TIDMVAL

RNS Number : 6317P

ValiRx PLC

18 February 2021

("ValiRx", the "Company" or the "Group")

Director/PDMR Shareholdings

London, UK - ValiRx plc (AIM:VAL), a clinical stage drug development company, announces that it has received notifications on 18 February 2021 of the following share purchases by certain Directors and PDMRs of the Company.

 
 Name                Number       Purchase   Date of      Number         Number            Percentage 
                      of shares    price      purchase     of shares      of shares         shareholding 
                      purchased                            held prior     held following    of issued 
                                                           to purchase    purchase          share capital 
                                                                                            following 
                                                                                            purchase 
 Kevin Cox 
  (Director)             22,000     22.25p   17/02/2021        250,333           272,333            0.42% 
                    -----------  ---------  -----------  -------------  ----------------  --------------- 
 Gerry Desler 
  (Director)             22,000     22.75p   18/02/2021         81,668           103,668            0.16% 
                    -----------  ---------  -----------  -------------  ----------------  --------------- 
 Martin Lampshire 
  (Director)             44,000     22.70p   18/02/2021              -            44,000            0.07% 
                    -----------  ---------  -----------  -------------  ----------------  --------------- 
 Mark Treharne 
  (PDMR)                  6,095     22.78p   17/02/2021              -             6,095            0.01% 
                    -----------  ---------  -----------  -------------  ----------------  --------------- 
 

Exercise of Warrants

Furthermore, the Company received notifications on 18 February 2021 for the exercise of warrants over 166,666 new ordinary shares in the Company at an exercise price of 13p each ("New Ordinary Shares") by Suzanne Dilly and Kevin Alexander, both Directors of the Company. Details of the exercise are set out in the table below.

 
 Name               Number of    Purchase   Number of      Number            Percentage 
                     warrants     price      shares held    of shares         shareholding 
                     exercised               prior to       held following    of issued 
                                             purchase       exercise          share capital 
                                                                              following 
                                                                              exercise 
 Suzanne Dilly      83,333       13.00p     233,335        316,668           0.49% 
                   -----------  ---------  -------------  ----------------  --------------- 
 Kevin Alexander    83,333       13.00p     167,500        250,833           0.39% 
                   -----------  ---------  -------------  ----------------  --------------- 
 

Total Voting Rights

The Company had previously applied to list these 166,666 ordinary shares as part of the block listing of 9,034,732 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") which was announced on 19 August 2020. They were admitted to trading on AIM on 24 August 2020.

The total voting rights of the Company comprise 65,049,156 Ordinary Shares which may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.

Ends

For further information please contact:

 
 ValiRx plc                                   Tel: +44 (0) 2476 
                                               796496 
                                               www.valirx.com 
 Suzanne Dilly, CEO                           Suzanne.Dilly@valirx.com 
 
   Cairn Financial Advisers LLP (Nominated      Tel: +44 (0) 20 7213 
   Adviser)                                     0880 
   Liam Murray / Jo Turner / Ludovico 
   Lazzaretti 
 
   Peterhouse Capital Limited (Sole Broker)     Tel: +44 (0) 20 7469 
   Duncan Vasey / Lucy Williams / Eran          0930 
   Zucker 
 
   Optimum Strategic Communications             Tel: +44 (0) 20 8148 
   Supriya Mathur/ Shabnam Bashir               3040 
                                                valirx@optimumcomms.com 
 

About ValiRx plc

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1      Details of the person discharging managerial responsibilities/person 
         closely associated 
-----  ----------------------------------------------------------------------------------------------------------- 
 a.     Name                                        a) Kevin Cox 
                                                     b) Gerry Desler 
                                                     c) Martin Lampshire 
                                                     d) Mark Treharne 
                                                  ---------------------------------------------------------------- 
 2      Reason for notification 
       -----------------------------------------  ---------------------------------------------------------------- 
 a.     Position/Status                            a) Director 
                                                    b) Director 
                                                    c) Director 
                                                    d) PDMR 
       -----------------------------------------  ---------------------------------------------------------------- 
 b.     Initial notification/                      Initial notification 
         Amendment 
       -----------------------------------------  ---------------------------------------------------------------- 
 3      Details of the issuer, emission allowance market participant, 
         auction platform, auctioneer or auction monitor 
       ----------------------------------------------------------------------------------------------------------- 
 a.     Name                                       ValiRx PLC 
       ----------------------------------------- 
 b.     LEI                                           213800VQKB9SJCQDET40 
       -----------------------------------------  ---------------------------------------------------------------- 
 4      Details of the transaction(s): section to be repeated for 
         (i) each type of instrument; (ii) each type of transaction; 
         (iii) each date; and (iv) each place where transactions have 
         been conducted 
-----  ----------------------------------------------------------------------------------------------------------- 
 a.     Description                                Ordinary Shares 
         of the financial 
         instrument,                                ISIN: GB00BLH13C52 
         type of instrument 
 
         Identification 
         Code 
       -----------------------------------------  ---------------------------------------------------------------- 
 b.     Nature of the                              On market Purchase 
         transaction 
       -----------------------------------------  ---------------------------------------------------------------- 
 
 c.     Price(s) and                                 Price(s)                                Volume(s) 
         volume(s) 
       -----------------------------------------    -------------------------------------- 
                                                      a) GBP 0.22250                          a) 22,000 
                                                       b) GBP 0.22745                         b) 22,000 
                                                       c) GBP 0.22700                         c) 44,000 
                                                       d) GBP 0.22780                          d) 6,095 
                                                    --------------------------------------  ---------------- 
 
 d.     Aggregated information 
         - Aggregated                                94,095 
         Volume 
         - Price                                     GBP0.22610 (weighted average price) 
       -----------------------------------------  ---------------------------------------------------------------- 
 e.     Date of the                                 a) 17/02/2021 
         transaction                                 b) 18/02/2021 
                                                     c) 18/02/2021 
                                                     d) 17/02/2021 
       -----------------------------------------  ---------------------------------------------------------------- 
 f.     Place of the                               London, UK 
         transaction 
       -----------------------------------------  ---------------------------------------------------------------- 
 
 
 
 Notification of a Transaction pursuant to Article 19(1) of Regulation 
  (EU) No. 596/2014 
 1       Details of the person discharging managerial responsibilities/person 
          closely associated 
------  ------------------------------------------------------------------------------------------------ 
 a.      Name                                    a) Suzanne Dilly 
                                                  b) Kevin Alexander 
                                               --------------------------------------------------------- 
 2       Reason for notification 
        -------------------------------------  --------------------------------------------------------- 
 a.      Position/Status                        a) Director 
                                                 b) Director 
        -------------------------------------  --------------------------------------------------------- 
 b.      Initial notification/                  Initial notification 
          Amendment 
        -------------------------------------  --------------------------------------------------------- 
 3       Details of the issuer, emission allowance market participant, 
          auction platform, auctioneer or auction monitor 
        ------------------------------------------------------------------------------------------------ 
 a.      Name                                   ValiRx PLC 
        ------------------------------------- 
 b.      LEI                                       213800VQKB9SJCQDET40 
        -------------------------------------  --------------------------------------------------------- 
 4       Details of the transaction(s): section to be repeated for 
          (i) each type of instrument; (ii) each type of transaction; 
          (iii) each date; and (iv) each place where transactions have 
          been conducted 
------  ------------------------------------------------------------------------------------------------ 
 a.      Description of                         Warrants over new ordinary shares 
          the financial 
          instrument, type                       ISIN: GB00BLH13C52 
          of instrument 
 
          Identification 
          Code 
        -------------------------------------  --------------------------------------------------------- 
 b.      Nature of the                          Exercise of warrants over new ordinary shares 
          transaction                            at an exercise price of 13p per share 
        -------------------------------------  --------------------------------------------------------- 
 
 c.      Price(s) and                                    Price(s)                 Volume(s) 
          volume(s) 
        -------------------------------------           ----------------------- 
                                                         a) GBP0.13               83,333 
     b) GBP0.13                                                                    83,333 
   ----------------------------------------------------------------------------  ------------------ 
 
 d.      Aggregated information 
          - Aggregated                            166,666 
          Volume                                  GBP0.13 
          - Price 
        -------------------------------------  --------------------------------------------------------- 
 e.      Date of the transaction                18/02/2021 
        -------------------------------------  --------------------------------------------------------- 
 f.      Place of the                           London, UK 
          transaction 
        -------------------------------------  --------------------------------------------------------- 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHBUGDDLXBDGBI

(END) Dow Jones Newswires

February 18, 2021 10:39 ET (15:39 GMT)

Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Valirx.
Valirx (LSE:VAL)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Valirx.